Form 4: Vigil Neuroscience Acquired by Sanofi

Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash plus a $2.00 contingent value right per share.

Summary

• Vigil Neuroscience, Inc. has been acquired by Sanofi, with its shares converted into cash and contingent value rights.
• The acquisition was completed on August 5, 2025, with Vesper Acquisition Sub Inc., a wholly owned subsidiary of Sanofi, merging into Vigil Neuroscience.
• Each share of Vigil Neuroscience Common Stock was converted into the right to receive $8.00 in cash (the 'Closing Amount') and one contingent value right (CVR).
• The CVR represents the right to receive an additional $2.00 in cash, conditioned upon the satisfaction of a certain clinical milestone.
• Restricted Stock Units (RSUs) outstanding immediately prior to the merger's effective time were accelerated, fully vested, cancelled, and converted into the Closing Amount plus one CVR per share.
• Stock options outstanding immediately prior to the merger's effective time were accelerated and fully vested.
• Stock options with an exercise price less than the Closing Amount ($8.00) were cancelled and converted into a cash amount equal to the product of the number of shares subject to the option multiplied by the excess of the Closing Amount over the exercise price, plus one CVR per share.

Sentiment

Score: 7

Explanation: The merger provides immediate cash value to shareholders and a potential additional payout via a CVR, indicating a successful exit for the company, despite its cessation as an independent entity.

Positives

• Shareholders received immediate cash consideration of $8.00 per share.
• Shareholders have the potential to receive an additional $2.00 per share via a Contingent Value Right (CVR) upon the achievement of a clinical milestone.
• Unvested Restricted Stock Units (RSUs) and stock options were accelerated and fully vested at the effective time of the merger, providing liquidity to equity award holders.

Negatives

• Vigil Neuroscience, Inc. ceased to be an independent, publicly traded company, becoming a wholly owned subsidiary of Sanofi.

Risks

• The $2.00 per share Contingent Value Right (CVR) payment is conditioned upon the satisfaction of a 'certain clinical milestone,' which may not be achieved, meaning the additional payment is not guaranteed.

Future Outlook

The Contingent Value Right (CVR) payment of $2.00 per share is contingent on a specific clinical milestone being met. This represents a potential future payout for former shareholders of Vigil Neuroscience.

Industry Context

This acquisition by Sanofi indicates a trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipeline assets or technological capabilities. It suggests Sanofi's strategic interest in Vigil Neuroscience's therapeutic areas.

Comparison to Industry Standards

• The cash-plus-CVR merger structure is a common approach in biotech acquisitions, allowing the acquirer to mitigate risk associated with the target company's pipeline assets by making a portion of the consideration contingent on future clinical or regulatory achievements.
• Specific comparable companies, projects, or results are not detailed in the filing to allow for a direct quantitative comparison.

Stakeholder Impact

• Shareholders: Received cash and a Contingent Value Right (CVR) for their shares, representing a liquidity event and potential future upside.
• Employees: Vigil Neuroscience became a wholly-owned subsidiary of Sanofi, which may lead to integration and potential changes in employment structure.

Next Steps

• Potential future payment of the $2.00 Contingent Value Right (CVR) upon achievement of the specified clinical milestone.

Key Dates

Keywords

Vigil Neuroscience, Sanofi, Merger, Acquisition, VIGL, SEC Form 4, Contingent Value Right, CVR, Biotechnology, Pharmaceutical